Medpacto Stock Net Income
| 235980 Stock | KRW 4,700 115.00 2.51% |
MedPacto fundamentals help investors to digest information that contributes to MedPacto's financial success or failures. It also enables traders to predict the movement of MedPacto Stock. The fundamental analysis module provides a way to measure MedPacto's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to MedPacto stock.
MedPacto |
MedPacto Company Net Income Analysis
MedPacto's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current MedPacto Net Income | (17.04 B) |
Most of MedPacto's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, MedPacto is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, MedPacto reported net income of (17.04 Billion). This is much lower than that of the sector and significantly lower than that of the Biotechnology industry. The net income for all Republic of Korea stocks is notably higher than that of the company.
MedPacto Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MedPacto's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of MedPacto could also be used in its relative valuation, which is a method of valuing MedPacto by comparing valuation metrics of similar companies.MedPacto is rated fifth in net income category among its peers.
MedPacto Fundamentals
| Return On Equity | -58.54 | |||
| Return On Asset | -0.25 | |||
| Current Valuation | 1.18 T | |||
| Shares Owned By Insiders | 33.90 % | |||
| Shares Owned By Institutions | 5.45 % | |||
| Gross Profit | (1.66 M) | |||
| EBITDA | (26.36 B) | |||
| Net Income | (17.04 B) | |||
| Cash And Equivalents | 1.29 B | |||
| Total Debt | 75.41 B | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 19.90 X | |||
| Cash Flow From Operations | (25.15 B) | |||
| Target Price | 26000.0 | |||
| Market Capitalization | 440.59 B | |||
| Total Asset | 133.35 B | |||
| Z Score | 3.0 | |||
| Net Asset | 133.35 B |
About MedPacto Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MedPacto's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MedPacto using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MedPacto based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with MedPacto
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if MedPacto position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in MedPacto will appreciate offsetting losses from the drop in the long position's value.Moving together with MedPacto Stock
| 0.61 | 207940 | Samsung Biologics | PairCorr |
| 0.68 | 302440 | SK Bioscience | PairCorr |
| 0.8 | 144510 | Green Cross Lab | PairCorr |
Moving against MedPacto Stock
The ability to find closely correlated positions to MedPacto could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace MedPacto when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back MedPacto - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling MedPacto to buy it.
The correlation of MedPacto is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as MedPacto moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if MedPacto moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for MedPacto can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in MedPacto Stock
MedPacto financial ratios help investors to determine whether MedPacto Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in MedPacto with respect to the benefits of owning MedPacto security.